vs

Side-by-side financial comparison of AWARE INC (AWRE) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.

AWARE INC is the larger business by last-quarter revenue ($3.4M vs $2.2M, roughly 1.5× Instil Bio, Inc.). On growth, AWARE INC posted the faster year-over-year revenue change (-6.2% vs -19.2%).

AWARE Inc. is a technology firm specializing in biometric software and identity verification solutions. It develops fingerprint, facial, and iris recognition tools, serving government agencies, financial institutions, and enterprise clients primarily across North America and global regulated markets.

Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.

AWRE vs TIL — Head-to-Head

Bigger by revenue
AWRE
AWRE
1.5× larger
AWRE
$3.4M
$2.2M
TIL
Growing faster (revenue YoY)
AWRE
AWRE
+13.0% gap
AWRE
-6.2%
-19.2%
TIL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AWRE
AWRE
TIL
TIL
Revenue
$3.4M
$2.2M
Net Profit
$-8.2M
Gross Margin
90.1%
Operating Margin
-107.8%
-426.3%
Net Margin
-365.3%
Revenue YoY
-6.2%
-19.2%
Net Profit YoY
31.1%
EPS (diluted)
$-1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AWRE
AWRE
TIL
TIL
Q1 26
$3.4M
Q4 25
$4.7M
$2.2M
Q3 25
$5.1M
$2.2M
Q2 25
$3.9M
$2.2M
Q1 25
$3.6M
$2.2M
Q4 24
$4.8M
$2.8M
Q3 24
$3.8M
$1.5M
Q2 24
$4.3M
$0
Net Profit
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
$-1.5M
$-8.2M
Q3 25
$-1.1M
$-13.6M
Q2 25
$-1.8M
$-21.4M
Q1 25
$-1.6M
$-28.2M
Q4 24
$-1.2M
$-11.9M
Q3 24
$-1.2M
$-23.0M
Q2 24
$-1.1M
$-14.9M
Gross Margin
AWRE
AWRE
TIL
TIL
Q1 26
90.1%
Q4 25
94.7%
Q3 25
90.4%
Q2 25
91.3%
Q1 25
93.2%
Q4 24
99.6%
Q3 24
93.0%
Q2 24
93.8%
Operating Margin
AWRE
AWRE
TIL
TIL
Q1 26
-107.8%
Q4 25
-31.1%
-426.3%
Q3 25
-25.2%
-670.0%
Q2 25
-50.3%
-1045.5%
Q1 25
-51.3%
-1363.2%
Q4 24
-30.7%
-426.1%
Q3 24
-38.1%
-1582.8%
Q2 24
-31.0%
Net Margin
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
-31.2%
-365.3%
Q3 25
-20.5%
-606.0%
Q2 25
-45.4%
-954.2%
Q1 25
-44.3%
-1257.8%
Q4 24
-24.8%
-428.8%
Q3 24
-30.3%
-1541.9%
Q2 24
-25.2%
EPS (diluted)
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
$-0.07
$-1.13
Q3 25
$-0.05
$-2.01
Q2 25
$-0.08
$-3.24
Q1 25
$-0.08
$-4.32
Q4 24
$-0.05
$-1.82
Q3 24
$-0.06
$-3.54
Q2 24
$-0.05
$-2.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AWRE
AWRE
TIL
TIL
Cash + ST InvestmentsLiquidity on hand
$4.6M
$6.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$113.9M
Total Assets
$33.2M
$203.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AWRE
AWRE
TIL
TIL
Q1 26
$4.6M
Q4 25
$7.3M
$6.6M
Q3 25
$6.3M
$5.8M
Q2 25
$7.3M
$7.7M
Q1 25
$8.5M
$15.4M
Q4 24
$13.0M
$8.8M
Q3 24
$11.2M
$6.7M
Q2 24
$11.5M
$6.8M
Stockholders' Equity
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
$26.1M
$113.9M
Q3 25
$27.2M
$120.4M
Q2 25
$28.1M
$131.7M
Q1 25
$29.5M
$144.9M
Q4 24
$30.9M
$169.4M
Q3 24
$31.9M
$176.3M
Q2 24
$32.6M
$195.0M
Total Assets
AWRE
AWRE
TIL
TIL
Q1 26
$33.2M
Q4 25
$37.2M
$203.5M
Q3 25
$40.3M
$211.8M
Q2 25
$38.1M
$231.0M
Q1 25
$39.9M
$237.4M
Q4 24
$42.6M
$263.6M
Q3 24
$43.7M
$272.6M
Q2 24
$43.2M
$294.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AWRE
AWRE
TIL
TIL
Operating Cash FlowLast quarter
$-7.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
$1.0M
$-7.1M
Q3 25
$-2.4M
$-10.6M
Q2 25
$-1.2M
$-14.8M
Q1 25
$-2.9M
$-4.2M
Q4 24
$683.0K
$-10.6M
Q3 24
$-765.0K
$-20.1M
Q2 24
$-668.0K
$-10.6M
Free Cash Flow
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
$926.0K
Q3 25
Q2 25
Q1 25
$-3.0M
Q4 24
Q3 24
Q2 24
FCF Margin
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
19.9%
Q3 25
Q2 25
Q1 25
-82.7%
Q4 24
Q3 24
Q2 24
Capex Intensity
AWRE
AWRE
TIL
TIL
Q1 26
Q4 25
2.6%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
1.2%
Q4 24
0.0%
Q3 24
0.0%
0.0%
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons